Literature DB >> 15959831

Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

David S Segal1, Ronald Kuczenski, Meghan L O'Neil, William P Melega, Arthur K Cho.   

Abstract

The translational value of preclinical models of methamphetamine abuse depends in large part on the degree to which the drug regimens used in animals produce methamphetamine exposure patterns similar to those experienced by human methamphetamine abusers. To approximate one common form of methamphetamine abuse, we studied the effects of a schedule of intravenous methamphetamine administration in rats which included 2 weeks of progressively more frequent drug injections (0.125 mg/kg/injection) followed by 40 maintenance days during which animals received 40 daily injections (at 15-min intervals), with the dose gradually increasing (0.125-0.25 mg/kg per injection) every 5-10 days. This treatment produced an emerging behavioral profile characterized by gradually more continuous periods of activation consisting of progressively more intense, focused stereotypy interrupted by episodic bursts of locomotion. We also assessed markers of dopamine neurotransmission (dopamine transporter, vesicular monoamine transporter, and dopamine D1 and D2 receptors) at 15 min and (including dopamine levels) at 6 and 30 days following cessation of methamphetamine treatment. All dopamine components measured in caudate-putamen were significantly reduced at 15 min and 6 days after the final methamphetamine injection. Dopamine D1 and D2 receptors fully recovered after 30 days of drug abstinence, whereas dopamine and the dopamine transporter exhibited significant but incomplete recovery by this time point. In contrast, only the vesicular monoamine transporter exhibited no evidence of recovery over the 30-day withdrawal period. These data are discussed in terms of damage to dopamine terminals and compensatory adjustments in mechanisms maintaining functional dopaminergic transmission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15959831     DOI: 10.1007/s00213-005-2188-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

1.  Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users.

Authors:  K S Kalasinsky; T Z Bosy; G A Schmunk; G Reiber; R M Anthony; Y Furukawa; M Guttman; S J Kish
Journal:  Forensic Sci Int       Date:  2001-02-15       Impact factor: 2.395

2.  Escalating dose-binge stimulant exposure: relationship between emergent behavioral profile and differential caudate-putamen and nucleus accumbens dopamine responses.

Authors:  D S Segal; R Kuczenski
Journal:  Psychopharmacology (Berl)       Date:  1999-02       Impact factor: 4.530

Review 3.  Neuroadaptive effects of active versus passive drug administration in addiction research.

Authors:  Edwin H Jacobs; August B Smit; Taco J de Vries; Anton N M Schoffelmeer
Journal:  Trends Pharmacol Sci       Date:  2003-11       Impact factor: 14.819

4.  The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

Authors:  J M Wilson; S J Kish
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

5.  The vesicular monoamine transporter is not regulated by dopaminergic drug treatments.

Authors:  T Vander Borght; M Kilbourn; T Desmond; D Kuhl; K Frey
Journal:  Eur J Pharmacol       Date:  1995-12-29       Impact factor: 4.432

6.  Decreased striatal dopamine D1 receptor-stimulated adenylyl cyclase activity in human methamphetamine users.

Authors:  Junchao Tong; Brian M Ross; Gregory A Schmunk; Frank J Peretti; Kathryn S Kalasinsky; Yoshiaki Furukawa; Lee Cyn Ang; Sally S Aiken; Dennis J Wickham; Stephen J Kish
Journal:  Am J Psychiatry       Date:  2003-05       Impact factor: 18.112

7.  Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.

Authors:  K Frey; M Kilbourn; T Robinson
Journal:  Eur J Pharmacol       Date:  1997-09-10       Impact factor: 4.432

8.  Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal.

Authors:  W P Melega; A E Williams; D A Schmitz; E W DiStefano; A K Cho
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

9.  The bioavailability of intranasal and smoked methamphetamine.

Authors:  Debra S Harris; Harold Boxenbaum; E Thomas Everhart; Gina Sequeira; John E Mendelson; Reese T Jones
Journal:  Clin Pharmacol Ther       Date:  2003-11       Impact factor: 6.875

10.  Desensitization of rat striatal dopamine-stimulated adenylate cyclase after acute amphetamine administration.

Authors:  J V Barnett; R Kuczenski
Journal:  J Pharmacol Exp Ther       Date:  1986-06       Impact factor: 4.030

View more
  27 in total

Review 1.  The need for speed: an update on methamphetamine addiction.

Authors:  Alasdair M Barr; William J Panenka; G William MacEwan; Allen E Thornton; Donna J Lang; William G Honer; Tania Lecomte
Journal:  J Psychiatry Neurosci       Date:  2006-09       Impact factor: 6.186

Review 2.  Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review.

Authors:  Eun-Joo Shin; Hai-Quyen Tran; Phuong-Tram Nguyen; Ji Hoon Jeong; Seung-Yeol Nah; Choon-Gon Jang; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

3.  Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration.

Authors:  Goran Laćan; Martin Hadamitzky; Ronald Kuczenski; William P Melega
Journal:  Synapse       Date:  2013-03-19       Impact factor: 2.562

4.  Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine.

Authors:  Brook L Henry; Mark A Geyer; Mahalah R Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

5.  In vivo reduction of striatal D1R by RNA interference alters expression of D1R signaling-related proteins and enhances methamphetamine addiction in male rats.

Authors:  Alison D Kreisler; Michael J Terranova; Sucharita S Somkuwar; Dvijen C Purohit; Shanshan Wang; Brian P Head; Chitra D Mandyam
Journal:  Brain Struct Funct       Date:  2020-04-03       Impact factor: 3.270

Review 6.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

7.  Methamphetamine reduces LTP and increases baseline synaptic transmission in the CA1 region of mouse hippocampus.

Authors:  Jarod Swant; Sanika Chirwa; Gregg Stanwood; Habibeh Khoshbouei
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

8.  Regulation of sigma-1 receptors and endoplasmic reticulum chaperones in the brain of methamphetamine self-administering rats.

Authors:  Teruo Hayashi; Zuzana Justinova; Eri Hayashi; Gianfrancesco Cormaci; Tomohisa Mori; Shang-Yi Tsai; Chanel Barnes; Steven R Goldberg; Tsung-Ping Su
Journal:  J Pharmacol Exp Ther       Date:  2009-11-25       Impact factor: 4.030

9.  Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat.

Authors:  Irina N Krasnova; Zuzana Justinova; Bruce Ladenheim; Subramaniam Jayanthi; Michael T McCoy; Chanel Barnes; John E Warner; Steven R Goldberg; Jean Lud Cadet
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

10.  Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.

Authors:  Ronald Kuczenski; David S Segal; William P Melega; Goran Lacan; Stanley J McCunney
Journal:  Neuropsychopharmacology       Date:  2009-07-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.